Rapt Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

- confirmed objective response rate (orr) of 15.6% in all patients regardless of pd-l1 or hpv status - confirmed orr of 17.4% in subset of patients with pd-l1+ disease - confirmed orr of 22.2% in subset of patients with hpv+ disease - median duration of treatment in responders was 19.6 months at the time of data cutoff south san francisco, calif., april 09, 2024 (globe newswire) --  rapt therapeutics, inc. (nasdaq: rapt), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing phase 2 trial of tivumecirnon in combination with the anti-pd-1 checkpoint inhibitor (cpi) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (hnscc) whose disease progressed despite previous treatment with cpi therapy (cpi-experienced).

New york, march 11, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of rapt therapeutics, inc. ("rapt" or the "company") (nasdaq: rapt).  such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.

South san francisco, calif., march 07, 2024 (globe newswire) -- rapt therapeutics, inc. (nasdaq: rapt), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended december 31, 2023.

Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer

New york , march 3, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of rapt therapeutics, inc. ("rapt" or the "company") (nasdaq: rapt).  such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.

It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.

RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment due to liver failure in a trial participant.

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:

RAPT Therapeutics has solid data from early trials but has a habit of going down on good data. One reason could be that the stock is heavily institution-owned. Their next major catalyst is one year away.

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 1:20 p.m. PT.

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy -Data to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting   SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced biomarker data for FLX475 from its ongoing FLX475-02 Phase 1/2 clinical trial which corroborate the clinical activity of FLX475 reported in Epstein-Barr virus-positive (EBV+) lymphoma, EBV+ gastric cancer and non-small cell lung cancer (NSCLC), as well as the mechanism of this novel CCR4 antagonist.

RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammatory diseases and oncology. The pipeline of investigational therapies includes FLX475 as a potential treatment for advanced cancers and RPT193, which targets atopic dermatitis and asthma.

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.